TR199901602T2
(xx)
|
1996-10-18 |
1999-10-21 |
Vertex Pharmaceuticals Incorporated |
Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri.
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
US6323180B1
(en)
*
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
EP1257649B1
(en)
*
|
1999-06-25 |
2010-01-20 |
Paik Kwang Industrial Co., Ltd. |
Corynebacterium glutamicum genes encoding metabolic pathway proteins
|
DE60137207D1
(de)
|
2000-04-05 |
2009-02-12 |
Schering Corp |
Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
|
RU2002131163A
(ru)
|
2000-04-19 |
2004-06-27 |
Шеринг Корпорейшн (US) |
Макроциклические ингибиторы ns3-серинпротезы вируса гепатита с, содержащие алкил- и арилаланиновые p2 фрагменты
|
WO2001085720A1
(en)
|
2000-05-05 |
2001-11-15 |
Smithkline Beecham Corporation |
Novel anti-infectives
|
PE20011350A1
(es)
|
2000-05-19 |
2002-01-15 |
Vertex Pharma |
PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
|
MY143322A
(en)
|
2000-07-21 |
2011-04-15 |
Schering Corp |
Peptides as ns3-serine protease inhibitors of hepatitis c virus
|
AU8063701A
(en)
|
2000-07-21 |
2002-02-05 |
Schering Corp |
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
JP3889708B2
(ja)
*
|
2000-11-20 |
2007-03-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎トリペプチド阻害剤
|
US6911428B2
(en)
|
2000-12-12 |
2005-06-28 |
Schering Corporation |
Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
|
MY134070A
(en)
|
2001-01-22 |
2007-11-30 |
Isis Pharmaceuticals Inc |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
WO2003006490A1
(en)
|
2001-07-11 |
2003-01-23 |
Vertex Pharmaceuticals Incorporated |
Bridged bicyclic serine protease inhibitors
|
WO2003024747A1
(en)
|
2001-09-14 |
2003-03-27 |
Honda Giken Kogyo Kabushiki Kaisha |
Front grill impact-absorbing structure for a vehicle
|
EP2402009A1
(en)
|
2001-10-24 |
2012-01-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system
|
US20050009873A1
(en)
*
|
2001-11-02 |
2005-01-13 |
Gianpaolo Bravi |
Acyl dihydro pyrrole derivatives as hcv inhibitors
|
US6867185B2
(en)
*
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
TWI265927B
(en)
|
2002-01-23 |
2006-11-11 |
Schering Corp |
Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
|
US7119072B2
(en)
*
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
*
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2369970A1
(en)
*
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6642204B2
(en)
*
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2370396A1
(en)
*
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
CA2481369C
(en)
|
2002-04-11 |
2012-07-10 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
WO2004043339A2
(en)
*
|
2002-05-20 |
2004-05-27 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
AU2003299519A1
(en)
*
|
2002-05-20 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
ES2350201T3
(es)
*
|
2002-05-20 |
2011-01-20 |
Bristol-Myers Squibb Company |
Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c.
|
KR100457857B1
(ko)
*
|
2002-05-23 |
2004-11-18 |
(주) 비엔씨바이오팜 |
2-[2-(3-인돌릴)에틸아미노]피리딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물
|
TW200500375A
(en)
|
2002-06-28 |
2005-01-01 |
Idenix Cayman Ltd |
Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
|
US20040033959A1
(en)
*
|
2002-07-19 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
US7183302B2
(en)
*
|
2002-08-12 |
2007-02-27 |
Bristol-Myers Squibb Company |
Iminothiazolidinones as inhibitors of HCV replication
|
EP1408031A1
(en)
*
|
2002-10-09 |
2004-04-14 |
3 D Gene Pharma |
Pyrolidine derivatives useful in treatment of hepatitis C virus infection
|
DE60325498D1
(de)
|
2002-10-24 |
2009-02-05 |
Glaxo Group Ltd |
1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
US6908901B2
(en)
*
|
2003-03-05 |
2005-06-21 |
Boehringer Ingelheim International, Gmbh |
Hepatitis C inhibitor peptide analogs
|
WO2004101605A1
(en)
*
|
2003-03-05 |
2004-11-25 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibiting compounds
|
KR100960802B1
(ko)
*
|
2003-03-08 |
2010-06-01 |
주식회사유한양행 |
씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
|
US7148347B2
(en)
*
|
2003-04-10 |
2006-12-12 |
Boehringer Ingelheim International Gmbh |
Process for preparing macrocyclic compounds
|
JP4733023B2
(ja)
*
|
2003-04-16 |
2011-07-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
|
US6846836B2
(en)
|
2003-04-18 |
2005-01-25 |
Bristol-Myers Squibb Company |
N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
|
ES2535147T3
(es)
|
2003-04-18 |
2015-05-06 |
Enanta Pharmaceuticals, Inc. |
Compuestos macrocíclicos de quinoxalinilo que inhiben las serina proteasas de la hepatitis C
|
US7176208B2
(en)
*
|
2003-04-18 |
2007-02-13 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
|
EP1654261B1
(en)
*
|
2003-05-21 |
2007-11-14 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibitor compounds
|
CA2734066A1
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
US7273851B2
(en)
*
|
2003-06-05 |
2007-09-25 |
Enanta Pharmaceuticals, Inc. |
Tri-peptide hepatitis C serine protease inhibitors
|
WO2004113365A2
(en)
*
|
2003-06-05 |
2004-12-29 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c serine protease tri-peptide inhibitors
|
US7125845B2
(en)
*
|
2003-07-03 |
2006-10-24 |
Enanta Pharmaceuticals, Inc. |
Aza-peptide macrocyclic hepatitis C serine protease inhibitors
|
EP1658302B1
(en)
|
2003-07-25 |
2010-08-25 |
IDENIX Pharmaceuticals, Inc. |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
|
EP1664090A2
(en)
|
2003-08-26 |
2006-06-07 |
Schering Corporation |
Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
PE20050374A1
(es)
|
2003-09-05 |
2005-05-30 |
Vertex Pharma |
Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
|
US7642235B2
(en)
*
|
2003-09-22 |
2010-01-05 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
JP4525982B2
(ja)
|
2003-09-26 |
2010-08-18 |
シェーリング コーポレイション |
C型肝炎ウイルスのns3セリンプロテアーゼの大環状インヒビター
|
TW200528472A
(en)
|
2003-10-10 |
2005-09-01 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
|
PL1680137T3
(pl)
|
2003-10-14 |
2013-04-30 |
F Hoffmann La Roche Ltd |
Makrocykliczny kwas karboksylowy i związek acylosulfonamidowy jako inhibitor replikacji HCV
|
US7491794B2
(en)
*
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
KR20060120166A
(ko)
|
2003-10-27 |
2006-11-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Hcv ns3-ns4a 단백질분해효소 저항성 돌연변이
|
EP1944042A1
(en)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinations for HCV treatment
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
US20050119318A1
(en)
*
|
2003-10-31 |
2005-06-02 |
Hudyma Thomas W. |
Inhibitors of HCV replication
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN1902216A
(zh)
*
|
2003-11-20 |
2007-01-24 |
先灵公司 |
丙肝病毒ns3蛋白酶的去肽化抑制剂
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2007513200A
(ja)
*
|
2003-12-08 |
2007-05-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
超臨界流体処理によるルテニウム副生物の除去
|
CA2549660A1
(en)
|
2003-12-15 |
2005-06-30 |
Japan Tobacco Inc. |
Cyclopropane compounds and pharmaceutical use thereof
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
EP1730167B1
(en)
*
|
2004-01-21 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Macrocyclic peptides active against the hepatitis c virus
|
DE602005019979D1
(en)
*
|
2004-01-30 |
2010-04-29 |
Medivir Ab |
Hcv ns-3 serine protease inhibitoren
|
SE0400199D0
(sv)
*
|
2004-01-30 |
2004-01-30 |
Medivir Ab |
HCV Protease inhbitors
|
AU2005212257A1
(en)
|
2004-02-04 |
2005-08-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
CN103304541A
(zh)
|
2004-02-20 |
2013-09-18 |
贝林格尔.英格海姆国际有限公司 |
病毒聚合酶抑制剂
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
EP2206715A1
(en)
|
2004-02-24 |
2010-07-14 |
Japan Tobacco, Inc. |
Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor
|
JP2007525521A
(ja)
*
|
2004-02-27 |
2007-09-06 |
シェーリング コーポレイション |
C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物
|
EP1748983A2
(en)
|
2004-02-27 |
2007-02-07 |
Schering Corporation |
Compounds as inhibitors of hepatitis c virus ns3 serine protease
|
DE602005015093D1
(de)
|
2004-02-27 |
2009-08-06 |
Schering Corp |
Neue verbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
EP1737821B1
(en)
|
2004-02-27 |
2009-08-05 |
Schering Corporation |
3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
CN103102389A
(zh)
*
|
2004-02-27 |
2013-05-15 |
默沙东公司 |
作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物
|
WO2005085275A1
(en)
|
2004-02-27 |
2005-09-15 |
Schering Corporation |
Inhibitors of hepatitis c virus ns3 protease
|
US7635694B2
(en)
|
2004-02-27 |
2009-12-22 |
Schering Corporation |
Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
|
KR101135765B1
(ko)
*
|
2004-03-12 |
2012-04-23 |
버텍스 파마슈티칼스 인코포레이티드 |
아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
|
DE602005019700D1
(de)
|
2004-03-15 |
2010-04-15 |
Boehringer Ingelheim Int |
E, die sich für die behandlung von hepatitis-c-virusinfektionen eignen
|
WO2005095403A2
(en)
*
|
2004-03-30 |
2005-10-13 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
WO2005107742A1
(en)
|
2004-05-05 |
2005-11-17 |
Yale University |
Novel antiviral helioxanthin analogs
|
CN1984922A
(zh)
|
2004-05-20 |
2007-06-20 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
|
CA2568008C
(en)
*
|
2004-05-25 |
2014-01-28 |
Boehringer Ingelheim International Gmbh |
Process for preparing acyclic hcv protease inhibitors
|
WO2005123087A2
(en)
|
2004-06-15 |
2005-12-29 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
JP5080973B2
(ja)
|
2004-06-24 |
2012-11-21 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Rna依存性rnaウイルスの感染を処置するためのヌクレオシドアリールホスホルアミダート
|
JP4914348B2
(ja)
*
|
2004-06-28 |
2012-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎インヒビターペプチド類似体
|
WO2006020276A2
(en)
|
2004-07-16 |
2006-02-23 |
Gilead Sciences, Inc. |
Antiviral compounds
|
ATE512971T1
(de)
*
|
2004-07-20 |
2011-07-15 |
Boehringer Ingelheim Int |
Peptidanaloga als hepatitis c-hemmer
|
UY29016A1
(es)
*
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
EP1789074A4
(en)
*
|
2004-08-09 |
2009-08-12 |
Alios Biopharma Inc |
PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
|
JP2008511633A
(ja)
|
2004-08-27 |
2008-04-17 |
シェーリング コーポレイション |
C型肝炎ウィルスns3セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
|
AU2005285045B2
(en)
*
|
2004-09-14 |
2011-10-13 |
Gilead Pharmasset Llc |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
WO2006030892A1
(ja)
*
|
2004-09-17 |
2006-03-23 |
Nippon Shinyaku Co., Ltd. |
複素環化合物の製造方法
|
CN101072575A
(zh)
|
2004-10-01 |
2007-11-14 |
威特克斯医药股份有限公司 |
Hcv ns3-ns4a蛋白酶抑制
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
BRPI0607817B8
(pt)
|
2005-03-08 |
2021-05-25 |
Boehringer Ingelheim Int |
compostos macrocíclicos e seu processo de preparação
|
WO2006119061A2
(en)
|
2005-05-02 |
2006-11-09 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
US7592336B2
(en)
*
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2546246A3
(en)
|
2005-05-13 |
2013-04-24 |
Virochem Pharma Inc. |
Compounds and methods for the treatment or prevention of flavivirus infections
|
AR055198A1
(es)
*
|
2005-06-02 |
2007-08-08 |
Schering Corp |
Formulaciones farmaceuticas y metodos de tratamiento que las utilizan
|
EP1891089B1
(en)
|
2005-06-02 |
2014-11-05 |
Merck Sharp & Dohme Corp. |
HCV protease inhibitors in combination with food
|
US20060276404A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
JP2008546708A
(ja)
|
2005-06-17 |
2008-12-25 |
ノバルティス アクチエンゲゼルシャフト |
Hcvにおけるサングリフェリンの使用
|
TWI449711B
(zh)
*
|
2005-06-30 |
2014-08-21 |
Virobay Inc |
C型肝炎病毒(hcv)抑制劑
|
US7608592B2
(en)
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1910378B1
(en)
*
|
2005-07-20 |
2012-06-20 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibitor peptide analogs
|
AR057456A1
(es)
*
|
2005-07-20 |
2007-12-05 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del vhc
|
JP5249028B2
(ja)
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
WO2007014923A1
(en)
|
2005-07-29 |
2007-02-08 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis c virus
|
AR057704A1
(es)
|
2005-07-29 |
2007-12-12 |
Tibotec Pharm Ltd |
Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto
|
JP5426164B2
(ja)
|
2005-07-29 |
2014-02-26 |
ヤンセン・アールアンドデイ・アイルランド |
C型肝炎ウイルスの大環式インヒビター
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
BRPI0614638A2
(pt)
|
2005-07-29 |
2011-04-12 |
Tibotec Pharm Ltd |
compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para a preparação dos mesmos, combinação e composição farmacêutica
|
BRPI0614637A2
(pt)
|
2005-07-29 |
2011-04-12 |
Tibotec Pharm Ltd |
inibidores macrocìclicos do vìrus da hepatite c
|
PE20070343A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Inhibidores macrociclicos del virus de la hepatitis c
|
JP5230414B2
(ja)
|
2005-07-29 |
2013-07-10 |
テイボテク・フアーマシユーチカルズ |
C型肝炎ウイルスの大環状阻害剤
|
CA2615896C
(en)
*
|
2005-08-01 |
2012-11-13 |
Merck & Co., Inc. |
Macrocyclic peptides as hcv ns3 protease inhibitors
|
CN101277950B
(zh)
|
2005-08-02 |
2013-03-27 |
弗特克斯药品有限公司 |
丝氨酸蛋白酶抑制剂
|
US7632821B2
(en)
|
2005-08-09 |
2009-12-15 |
Merck & Co., Inc. |
Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
|
CA2618682C
(en)
|
2005-08-12 |
2011-06-21 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
PL385229A1
(pl)
*
|
2005-08-19 |
2008-09-29 |
Vertex Pharmaceuticals Incorporated |
Sposoby i związki pośrednie
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
PL1934243T3
(pl)
|
2005-09-09 |
2011-10-31 |
Boehringer Ingelheim Int |
Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
|
EP1999129B1
(en)
|
2005-10-11 |
2010-12-29 |
Intermune, Inc. |
Compounds and methods for inhibiting hepatitis c viral replication
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2392589A3
(en)
|
2005-11-11 |
2012-06-20 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
EP2345652A1
(en)
|
2005-12-21 |
2011-07-20 |
Abbott Laboratories |
Antiviral compounds
|
WO2007081517A2
(en)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Anti-viral compounds
|
JP2009521479A
(ja)
*
|
2005-12-21 |
2009-06-04 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
CN102702194A
(zh)
*
|
2005-12-21 |
2012-10-03 |
雅培制药有限公司 |
抗病毒化合物
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
CA2643688A1
(en)
|
2006-02-27 |
2007-08-30 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
US20070213301A1
(en)
|
2006-03-08 |
2007-09-13 |
Achillion Pharmaceuticals, Inc. |
Substituted Aminothiazole Derivatives With Anti-HCV Activity
|
NZ571280A
(en)
|
2006-03-16 |
2011-10-28 |
Vertex Pharma |
Deuterated hepatitis C protease inhibitors
|
KR101059593B1
(ko)
|
2006-04-11 |
2011-08-25 |
노파르티스 아게 |
Hcv/hiv 억제제 및 이들의 용도
|
GB0609492D0
(en)
*
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
WO2007137080A2
(en)
|
2006-05-23 |
2007-11-29 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
US8268776B2
(en)
|
2006-06-06 |
2012-09-18 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
US20080187516A1
(en)
*
|
2006-06-06 |
2008-08-07 |
Ying Sun |
Acyclic oximyl hepatitis c protease inhibitors
|
US7728148B2
(en)
*
|
2006-06-06 |
2010-06-01 |
Enanta Pharmaceuticals, Inc. |
Acyclic oximyl hepatitis C protease inhibitors
|
US9526769B2
(en)
|
2006-06-06 |
2016-12-27 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
GB0612423D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
PE20080992A1
(es)
*
|
2006-06-26 |
2008-08-06 |
Enanta Pharm Inc |
Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
|
RU2008152171A
(ru)
*
|
2006-07-05 |
2010-08-10 |
Интермьюн, Инк. (Us) |
Новые ингибиторы вирусной репликации гепатита с
|
EP2049474B1
(en)
|
2006-07-11 |
2015-11-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US7718612B2
(en)
*
|
2007-08-02 |
2010-05-18 |
Enanta Pharmaceuticals, Inc. |
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
|
US20090035267A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Moore Joel D |
Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
|
US7635683B2
(en)
*
|
2006-08-04 |
2009-12-22 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl tripeptide hepatitis C virus inhibitors
|
US7582605B2
(en)
*
|
2006-08-11 |
2009-09-01 |
Enanta Pharmaceuticals, Inc. |
Phosphorus-containing hepatitis C serine protease inhibitors
|
US20080038225A1
(en)
*
|
2006-08-11 |
2008-02-14 |
Ying Sun |
Triazolyl acyclic hepatitis c serine protease inhibitors
|
US7687459B2
(en)
*
|
2006-08-11 |
2010-03-30 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis C virus protease inhibitors
|
US7605126B2
(en)
|
2006-08-11 |
2009-10-20 |
Enanta Pharmaceuticals, Inc. |
Acylaminoheteroaryl hepatitis C virus protease inhibitors
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
US20090098085A1
(en)
*
|
2006-08-11 |
2009-04-16 |
Ying Sun |
Tetrazolyl acyclic hepatitis c serine protease inhibitors
|
WO2008022006A2
(en)
*
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis c virus protease inhibitors
|
MX2009000882A
(es)
|
2006-08-17 |
2009-02-04 |
Boehringer Ingelheim Int |
Inhibidores de la polimerasa virica.
|
WO2008063727A2
(en)
*
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
EP2079479B1
(en)
*
|
2006-10-24 |
2014-11-26 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
EP2079480B1
(en)
*
|
2006-10-24 |
2013-06-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
AU2007309546A1
(en)
*
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
BRPI0718161A2
(pt)
*
|
2006-10-27 |
2013-11-26 |
Merck & Co Inc |
Composto, composição farmacêutica, e, uso do composto.
|
CA2667032A1
(en)
*
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
WO2008057995A2
(en)
*
|
2006-11-02 |
2008-05-15 |
Taigen Biotechnology Co., Ltd. |
Hcv protease inhibitors
|
US7772180B2
(en)
*
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
RS52874B
(en)
|
2006-11-15 |
2013-12-31 |
Vertex Pharmaceuticals Incorporated |
THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8637663B2
(en)
|
2006-11-17 |
2014-01-28 |
Janssen R&D Ireland |
Macrocyclic inhibitors of hepatitis C virus
|
MX2009006056A
(es)
*
|
2006-12-07 |
2009-06-16 |
Schering Corp |
Formulacion de matriz sensible al ph.
|
GB0625349D0
(en)
*
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
TWI399380B
(zh)
*
|
2006-12-20 |
2013-06-21 |
Abbott Lab |
抗病毒化合物
|
GB0625345D0
(en)
*
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008075103A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Antiviral indoles
|
WO2008074035A1
(en)
*
|
2006-12-27 |
2008-06-19 |
Abbott Laboratories |
Hcv protease inhibitors and uses thereof
|
US20080207528A1
(en)
*
|
2007-02-01 |
2008-08-28 |
Syaulan Yang |
Hcv protease inhibitors
|
NZ579442A
(en)
|
2007-02-27 |
2012-02-24 |
Vertex Pharma |
Co-crystals of VX-950 (telaprevir) and other components, and pharmaceutical compositions comprising the same
|
AU2008219704A1
(en)
|
2007-02-27 |
2008-09-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
BRPI0808089A2
(pt)
|
2007-02-28 |
2014-07-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
WO2009008913A2
(en)
*
|
2007-03-23 |
2009-01-15 |
Schering Corporation |
P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US20080317712A1
(en)
*
|
2007-04-26 |
2008-12-25 |
Deqiang Niu |
Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
|
US8377872B2
(en)
|
2007-04-26 |
2013-02-19 |
Enanta Pharmaceuticals, Inc. |
Cyclic P3 tripeptide hepatitis C serine protease inhibitors
|
US20080267917A1
(en)
*
|
2007-04-26 |
2008-10-30 |
Deqiang Niu |
N-functionalized amides as hepatitis c serine protease inhibitors
|
US7910587B2
(en)
*
|
2007-04-26 |
2011-03-22 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl dipeptide hepatitis C virus inhibitors
|
US20080292587A1
(en)
*
|
2007-04-26 |
2008-11-27 |
Ying Sun |
Oximyl dipeptide hepatitis c protease inhibitors
|
SG174809A1
(en)
*
|
2007-05-03 |
2011-10-28 |
Intermune Inc |
Macrocyclic compounds useful as inhibitors of hepatitis c virus
|
EP2142215B1
(en)
|
2007-05-04 |
2012-03-07 |
Vertex Pharmceuticals Incorporated |
Combination therapy for the treatment of hcv infection
|
KR20090130347A
(ko)
*
|
2007-05-09 |
2009-12-22 |
화이자 인코포레이티드 |
치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도
|
AR066528A1
(es)
*
|
2007-05-10 |
2009-08-26 |
Array Biopharma Inc |
Peptidos inhibidores de la replicacion del virus de la hepatitis c
|
GB0709791D0
(en)
*
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
AR068794A1
(es)
*
|
2007-06-29 |
2009-12-09 |
Gilead Sciences Inc |
Compuestos antivirales
|
TWI395746B
(zh)
*
|
2007-06-29 |
2013-05-11 |
Gilead Sciences Inc |
抗病毒性化合物
|
JP2010533699A
(ja)
*
|
2007-07-17 |
2010-10-28 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
C型肝炎感染症の治療のための大環状インドール誘導体
|
EP2178902B1
(en)
*
|
2007-07-19 |
2012-11-28 |
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. |
Macrocyclic compounds as antiviral agents
|
JP2010535156A
(ja)
|
2007-08-03 |
2010-11-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ウイルスポリメラーゼ阻害剤
|
US8492546B2
(en)
|
2007-08-30 |
2013-07-23 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
US8419332B2
(en)
*
|
2007-10-19 |
2013-04-16 |
Atlas Bolt & Screw Company Llc |
Non-dimpling fastener
|
WO2009055335A2
(en)
*
|
2007-10-25 |
2009-04-30 |
Taigen Biotechnology Co., Ltd. |
Hcv protease inhibitors
|
US8383583B2
(en)
|
2007-10-26 |
2013-02-26 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
|
CN102026544A
(zh)
|
2007-11-14 |
2011-04-20 |
益安药业 |
大环四唑基丙型肝炎病毒丝氨酸蛋白酶抑制剂
|
WO2009070692A1
(en)
*
|
2007-11-29 |
2009-06-04 |
Enanta Pharmaceuticals, Inc. |
C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
|
US8030307B2
(en)
*
|
2007-11-29 |
2011-10-04 |
Enanta Pharmaceuticals, Inc. |
Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
|
WO2009076166A2
(en)
*
|
2007-12-05 |
2009-06-18 |
Enanta Pharmaceuticals, Inc. |
Oximyl hcv serine protease inhibitors
|
US8940688B2
(en)
*
|
2007-12-05 |
2015-01-27 |
Enanta Pharmaceuticals, Inc. |
Fluorinated tripeptide HCV serine protease inhibitors
|
EP2224920A4
(en)
|
2007-12-06 |
2012-05-09 |
Enanta Pharm Inc |
PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
|
WO2009079353A1
(en)
|
2007-12-14 |
2009-06-25 |
Enanta Pharmaceuticals, Inc. |
Triazole-containing macrocyclic hcv serine protease inhibitors
|
EA201000948A1
(ru)
|
2007-12-19 |
2011-02-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Ингибиторы вирусной полимеразы
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
WO2009094443A1
(en)
*
|
2008-01-24 |
2009-07-30 |
Enanta Pharmaceuticals, Inc. |
Difluorinated tripeptides as hcv serine protease inhibitors
|
JP2011510926A
(ja)
*
|
2008-01-24 |
2011-04-07 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
ヘテロアリール含有トリペプチドhcvセリンプロテアーゼ阻害剤
|
TW200936131A
(en)
|
2008-02-04 |
2009-09-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
CA2713108A1
(en)
*
|
2008-02-07 |
2009-08-13 |
Virobay, Inc. |
Inhibitors of cathepsin b
|
WO2009108507A1
(en)
|
2008-02-25 |
2009-09-03 |
Merck & Co., Inc. |
Therapeutic compounds
|
WO2009117594A1
(en)
*
|
2008-03-20 |
2009-09-24 |
Enanta Pharmaceuticals, Inc. |
Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
CA2720729A1
(en)
|
2008-04-15 |
2009-11-26 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2009134624A1
(en)
*
|
2008-04-28 |
2009-11-05 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
US8211891B2
(en)
*
|
2008-04-30 |
2012-07-03 |
Enanta Pharmaceuticals, Inc. |
Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
|
US20090285774A1
(en)
*
|
2008-05-15 |
2009-11-19 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CN101580535B
(zh)
*
|
2008-05-16 |
2012-10-03 |
太景生物科技股份有限公司 |
丙型肝炎病毒蛋白酶抑制剂
|
JP5529120B2
(ja)
|
2008-05-29 |
2014-06-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
ES2458358T3
(es)
|
2008-07-02 |
2014-05-05 |
Idenix Pharmaceuticals, Inc. |
Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
|
UA100436C2
(en)
*
|
2008-07-22 |
2012-12-25 |
Mepk Шарп Энд Доме Корп. |
Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
|
ES2383273T3
(es)
|
2008-07-23 |
2012-06-19 |
F. Hoffmann-La Roche Ag |
Compuestos heterocíclicos antivíricos
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
JP5520301B2
(ja)
|
2008-09-16 |
2014-06-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
強力なhcv阻害剤である2−チアゾリル−4−キノリニル−オキシ誘導体の結晶形態
|
CA2737376A1
(en)
*
|
2008-09-17 |
2010-03-25 |
Boehringer Ingelheim International Gmbh |
Combination of hcv ns3 protease inhibitor with interferon and ribavirin
|
BRPI0920513A2
(pt)
|
2008-09-26 |
2019-09-24 |
F Hoffamann La Roche Ag |
derivados de pirina ou pirazina para tratar hcv
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010039801A2
(en)
|
2008-10-02 |
2010-04-08 |
The J. David Gladstone Institutes |
Methods of treating hepatitis c virus infection
|
KR20110075019A
(ko)
*
|
2008-10-15 |
2011-07-05 |
인터뮨, 인크. |
치료용 항바이러스성 펩티드
|
WO2010049331A1
(en)
|
2008-10-30 |
2010-05-06 |
F. Hoffmann-La Roche Ag |
Heterocyclic antiviral arylpyridone derivatives
|
US20120101049A1
(en)
*
|
2008-11-21 |
2012-04-26 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical Composition Of A Potent HCV Inhibitor For Oral Administration
|
PT2373172E
(pt)
|
2008-12-03 |
2013-10-21 |
Presidio Pharmaceuticals Inc |
Inibidores de ns5a de hcv
|
MX2011005896A
(es)
|
2008-12-03 |
2011-09-29 |
Presidio Pharmaceuticals Inc |
Inhibidores de hcv ns5a.
|
US20100272674A1
(en)
*
|
2008-12-04 |
2010-10-28 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
UY32325A
(es)
*
|
2008-12-19 |
2010-07-30 |
Gilead Sciences Inc |
Inhibidores de ns3 proteasa del vhc
|
AU2009330333A1
(en)
|
2008-12-22 |
2011-07-07 |
Gilead Sciences, Inc. |
Antiviral compounds
|
EP2379534A1
(en)
|
2008-12-22 |
2011-10-26 |
F. Hoffmann-La Roche AG |
Heterocyclic antiviral compounds
|
BRPI0922508A8
(pt)
|
2008-12-23 |
2016-01-19 |
Pharmasset Inc |
Análogos de nucleosídeo
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
RU2011127080A
(ru)
|
2009-01-07 |
2013-02-20 |
Сайнексис, Инк. |
Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
TW201035083A
(en)
|
2009-03-06 |
2010-10-01 |
Hoffmann La Roche |
Heterocyclic antiviral compounds
|
JP2012520884A
(ja)
|
2009-03-18 |
2012-09-10 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー |
フラビウイルス科ウイルス感染症を治療する方法および組成物
|
CA2755658A1
(en)
|
2009-03-27 |
2010-09-30 |
Presidio Pharmaceuticals, Inc. |
Fused ring inhibitors of hepatitis c
|
WO2010118009A1
(en)
*
|
2009-04-06 |
2010-10-14 |
Ptc Therapeutics, Inc. |
Hcv inhibitor and therapeutic agent combinations
|
JP2012523419A
(ja)
|
2009-04-08 |
2012-10-04 |
イデニク プハルマセウティカルス,インコーポレイテッド |
大環状セリンプロテアーゼ阻害剤
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
CA2758838A1
(en)
|
2009-04-25 |
2010-10-28 |
F. Hoffmann-La Roche Ag |
Heterocyclic antiviral compounds
|
MX2011012155A
(es)
|
2009-05-13 |
2012-02-28 |
Enanta Pharm Inc |
Compuestos macrociclicos como inhibidores del virus de hepatitis c.
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI598358B
(zh)
*
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
AR077004A1
(es)
*
|
2009-06-09 |
2011-07-27 |
Hoffmann La Roche |
Compuestos heterociclicos antivirales
|
CA2762675A1
(en)
|
2009-06-24 |
2010-12-29 |
F. Hoffmann-La Roche Ag |
Heterocyclic antiviral compound
|
US8232246B2
(en)
*
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
WO2011003063A2
(en)
*
|
2009-07-02 |
2011-01-06 |
Dr. Reddy's Laboratories Ltd. |
Enzymes and methods for resolving amino vinyl cyclopropane carboxylic acid derivatives
|
CN102470103B
(zh)
|
2009-07-07 |
2016-09-07 |
贝林格尔.英格海姆国际有限公司 |
用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
|
WO2011014487A1
(en)
|
2009-07-30 |
2011-02-03 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
US8742162B2
(en)
|
2009-08-10 |
2014-06-03 |
Sumitomo Chemical Company, Limited |
Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester
|
US8324417B2
(en)
|
2009-08-19 |
2012-12-04 |
Virobay, Inc. |
Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
|
PL2477980T3
(pl)
*
|
2009-09-15 |
2017-02-28 |
Taigen Biotechnology Co., Ltd. |
Inhibitory proteazy hcv
|
AU2010298028A1
(en)
*
|
2009-09-28 |
2012-04-19 |
Intermune, Inc. |
Cyclic peptide inhibitors of hepatitis C virus replication
|
WO2011049908A2
(en)
*
|
2009-10-19 |
2011-04-28 |
Enanta Pharmaceuticals, Inc. |
Bismacrokyclic compounds as hepatitis c virus inhibitors
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
JP2013512247A
(ja)
|
2009-11-25 |
2013-04-11 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染症の治療または予防のための5−アルキニル−チオフェン−2−カルボン酸誘導体およびそれらの使用
|
CA2784748A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
CN102883718A
(zh)
|
2009-12-24 |
2013-01-16 |
顶点制药公司 |
用于治疗或预防黄病毒感染的类似物
|
US20110178107A1
(en)
*
|
2010-01-20 |
2011-07-21 |
Taigen Biotechnology Co., Ltd. |
Hcv protease inhibitors
|
US8653025B2
(en)
|
2010-01-27 |
2014-02-18 |
AB Pharma Ltd. |
Polyheterocyclic compounds highly potent as HCV inhibitors
|
US8530497B2
(en)
|
2010-03-11 |
2013-09-10 |
Boehringer Ingelheim International Gmbh |
Crystalline salts of a potent HCV inhibitor
|
JP2013522377A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
TW201139438A
(en)
|
2010-03-24 |
2011-11-16 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
EP2550268A1
(en)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
WO2011119853A1
(en)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
PT2752422T
(pt)
|
2010-03-31 |
2017-11-07 |
Gilead Pharmasset Llc |
Síntese estereosseletiva de princípios ativos contendo fósforo
|
EP2552203B1
(en)
|
2010-04-01 |
2017-03-22 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2575866A4
(en)
|
2010-05-24 |
2013-10-16 |
Presidio Pharmaceuticals Inc |
HCV NS5A INHIBITORS
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
EP2582717A2
(en)
|
2010-06-15 |
2013-04-24 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b polymerase mutants
|
UY33473A
(es)
|
2010-06-28 |
2012-01-31 |
Vertex Pharma |
Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
|
WO2012006070A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
WO2012006060A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
CN103153978A
(zh)
|
2010-08-17 |
2013-06-12 |
沃泰克斯药物股份有限公司 |
用于治疗或预防黄病毒科病毒感染的化合物和方法
|
MX343275B
(es)
|
2010-09-21 |
2016-10-31 |
Enanta Pharm Inc |
Prolina macrociclica derivada de inhibidores de serina proteasa de vhc.
|
AU2011310761A1
(en)
|
2010-09-30 |
2013-02-21 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating HCV infection
|
EA201390532A1
(ru)
|
2010-10-08 |
2013-09-30 |
Новартис Аг |
Композиции сульфамидых ингибиторов ns3, содержащие витамин е
|
PT3042910T
(pt)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-espiro-nucleósidos para utilização na terapia da hepatite c
|
CN103354808B
(zh)
*
|
2010-12-16 |
2016-08-10 |
Abbvie公司 |
抗病毒化合物
|
EP2658859A4
(en)
|
2010-12-30 |
2014-07-30 |
Enanta Pharm Inc |
MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
|
PE20140039A1
(es)
|
2010-12-30 |
2014-03-01 |
Enanta Pharm Inc |
Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
JP2014514295A
(ja)
|
2011-03-31 |
2014-06-19 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8962810B2
(en)
|
2011-06-16 |
2015-02-24 |
AB Pharma Ltd. |
Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
|
US20140142337A1
(en)
|
2011-06-21 |
2014-05-22 |
Mitsubishi Gas Chemical Company, Inc. |
1-amino-2-vinylcyclopropane carboxylic acid amide and salt thereof, and method for producing same
|
US20120328565A1
(en)
|
2011-06-24 |
2012-12-27 |
Brinkman John A |
Antiviral compounds
|
CN102807607B
(zh)
*
|
2011-07-22 |
2013-10-23 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
AR087346A1
(es)
|
2011-07-26 |
2014-03-19 |
Vertex Pharma |
Formulaciones de compuestos de tiofeno
|
DE102012016127A1
(de)
|
2011-08-31 |
2013-02-28 |
Daniel Elias |
Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
EP2755985B1
(en)
|
2011-09-12 |
2017-11-01 |
Idenix Pharmaceuticals LLC |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US9180193B2
(en)
|
2011-10-10 |
2015-11-10 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
AR089650A1
(es)
|
2011-10-14 |
2014-09-10 |
Idenix Pharmaceuticals Inc |
Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
AR088463A1
(es)
|
2011-10-21 |
2014-06-11 |
Abbvie Inc |
Metodos para el tratamiento de hcv
|
TWI532485B
(zh)
|
2011-10-21 |
2016-05-11 |
艾伯維有限公司 |
治療c型肝炎病毒(hcv)的方法
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
US9328138B2
(en)
|
2011-11-15 |
2016-05-03 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013082476A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
SG11201402899TA
(en)
|
2011-12-06 |
2014-07-30 |
Univ Leland Stanford Junior |
Methods and compositions for treating viral diseases
|
WO2013087743A1
(en)
|
2011-12-16 |
2013-06-20 |
F. Hoffmann-La Roche Ag |
Inhibitors of hcv ns5a
|
DK2794629T3
(en)
|
2011-12-20 |
2017-07-24 |
Riboscience Llc |
2 ', 4'-DIFLUOR-2'-METHYL-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
|
CN108409820A
(zh)
|
2011-12-20 |
2018-08-17 |
里博科学有限责任公司 |
作为hcv rna复制抑制剂的4′-叠氮基,3′-氟取代的核苷衍生物
|
AU2013208024A1
(en)
|
2012-01-12 |
2014-07-10 |
Boehringer Ingelheim International Gmbh |
Stabilized pharmaceutical formulations of a potent HCV inhibitor
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
JP6092261B2
(ja)
*
|
2012-02-24 |
2017-03-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗ウイルス化合物
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
WO2013142157A1
(en)
|
2012-03-22 |
2013-09-26 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
WO2013147750A1
(en)
|
2012-03-27 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Oral combination therapy for treating hcv infection in specific patient sub-population
|
WO2013147749A1
(en)
|
2012-03-27 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Oral combination therapy for treating hcv infection in specific patient subgenotype populations
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
MD20140134A2
(ro)
|
2012-05-22 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
MX353422B
(es)
|
2012-10-08 |
2018-01-12 |
Idenix Pharmaceuticals Llc |
Análogos de 2'-cloronucleósido para infección por vhc.
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
KR20150074051A
(ko)
|
2012-10-19 |
2015-07-01 |
브리스톨-마이어스 스큅 컴퍼니 |
C형 간염 바이러스 억제제
|
EP2909222B1
(en)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
2',4'-bridged nucleosides for hcv infection
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070964A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9334279B2
(en)
|
2012-11-02 |
2016-05-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914614B1
(en)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
CN103804208B
(zh)
*
|
2012-11-14 |
2016-06-08 |
重庆博腾制药科技股份有限公司 |
一种丙肝药物中间体的制备方法
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
EP2920195A1
(en)
|
2012-11-14 |
2015-09-23 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
RU2015132550A
(ru)
|
2013-01-23 |
2017-03-02 |
Ф. Хоффманн-Ля Рош Аг |
Противовирусные производные триазола
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
US20150065439A1
(en)
|
2013-02-28 |
2015-03-05 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
BR112015021429A2
(pt)
|
2013-03-05 |
2017-07-18 |
Hoffmann La Roche |
compostos antivirais
|
US9580463B2
(en)
|
2013-03-07 |
2017-02-28 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014138374A1
(en)
|
2013-03-08 |
2014-09-12 |
Boehringer Ingelheim International Gmbh |
Oral combination therapy for treating hcv infection in specific patient sub-population
|
AU2014236502A1
(en)
|
2013-03-14 |
2015-10-01 |
Achillion Pharmaceuticals, Inc. |
Processes for producing Sovaprevir
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
CN105307661A
(zh)
|
2013-05-16 |
2016-02-03 |
里博科学有限责任公司 |
4’-叠氮基,3’-脱氧基-3’-氟取代的核苷衍生物
|
UA123533C2
(uk)
|
2013-05-16 |
2021-04-21 |
Рібосаєнс Ллс |
4'-фтор-2'-метилзаміщені нуклеозидні похідні
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
PL3038601T3
(pl)
|
2013-08-27 |
2020-08-24 |
Gilead Pharmasset Llc |
Formulacja złożona dwóch związków przeciwwirusowych
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
US9717797B2
(en)
|
2013-12-05 |
2017-08-01 |
International Business Machines Corporation |
Polycarbonates bearing aromatic N-heterocycles for drug delivery
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
WO2015103490A1
(en)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Solid antiviral dosage forms
|
EP2899207A1
(en)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
New method for testing HCV protease inhibition
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
EP3113763A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
EP3448392A4
(en)
|
2016-04-28 |
2020-01-15 |
Emory University |
ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
|
WO2019060740A1
(en)
|
2017-09-21 |
2019-03-28 |
Riboscience Llc |
4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
|
KR20210098504A
(ko)
|
2018-12-04 |
2021-08-10 |
브리스톨-마이어스 스큅 컴퍼니 |
다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
|